CD8A and neoplasm: Astragalus polysaccharides (APS) reverse the decreasing trend of CD107a (a marker indicating the inhibition of CD8+ T cell activation) in inflammatory colorectal cancer models, inhibit the expression of STAT3 and activated Gal-3, and further reduce the expression of LAG3 in tumor-infiltrating CD8+ T cells—enhancing the killing ability of CD8+ T cells.